NEW YORK – Dovetail Genomics and CareDx said Wednesday that they have partnered on human leukocyte antigen (HLA) genotyping for organ and stem cell transplant matching.
As part of the collaboration, they will launch an early-access program for CareDx's next-generation sequencing-based AlloSeq Tx 17 HLA typing test, which incorporates Dovetail's LinkPrep NGS chromatin conformation assay.
Financial and other terms of the partnership were not disclosed.
"Through this partnership, HLA labs will gain early access to cutting-edge solutions, positioning them at the forefront of evaluating innovative donor-recipient matching methods," CareDx CEO John Hanna said in a statement.
The AlloSeq Tx 17 test analyzes more than the customary 11 HLA loci and includes the ability to provide HLA haplotypes by using Dovetail's Hi-C sequencing-based LinkPrep, launched in April, to provide phasing information from linked reads.
The firms noted that they will provide more data on the AlloSeq Tx assay at the American Society for Histocompatibility and Immunogenetics annual meeting this week.